Incidence of osteonecrosis of the jaw (ONJ) in metastatic renal cell cancer patients (mRCC) treated with zoledronic acid (ZA)

Authors :: Hajnalka Németh
Fruzsina Gyergyay
Lajos Géczi
Zsófia Küronya
Krisztián Nagyiványi
Krisztina Bíró
Source :: Journal of Clinical Oncology. 33:e20649-e20649
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: e20649 Background: Bisphosphonates inhibit bone resorption and thus bone renewal by suppressing the recruitment and activity of osteoclasts. Bisphosphonates are commonly used in the treatment of mR...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Incidence (epidemiology)
medicine.disease
Bone resorption
Zoledronic acid
Internal medicine
medicine
Osteonecrosis of the jaw
Metastatic renal cell cancer
business
medicine.drug

Tools